Entrada Therapeutics (TRDA) Competitors $17.60 +0.46 (+2.68%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRDA vs. ARWR, IDYA, AMPH, CGON, ACAD, SRRK, TWST, LBPH, KROS, and SWTXShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Amphastar Pharmaceuticals (AMPH), CG Oncology (CGON), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), Twist Bioscience (TWST), Longboard Pharmaceuticals (LBPH), Keros Therapeutics (KROS), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Arrowhead Pharmaceuticals IDEAYA Biosciences Amphastar Pharmaceuticals CG Oncology ACADIA Pharmaceuticals Scholar Rock Twist Bioscience Longboard Pharmaceuticals Keros Therapeutics SpringWorks Therapeutics Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Entrada Therapeutics (NASDAQ:TRDA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Do insiders and institutionals hold more shares of ARWR or TRDA? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ARWR or TRDA? Arrowhead Pharmaceuticals currently has a consensus target price of $45.33, indicating a potential upside of 132.60%. Entrada Therapeutics has a consensus target price of $21.50, indicating a potential upside of 22.16%. Given Arrowhead Pharmaceuticals' higher possible upside, research analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ARWR or TRDA? Arrowhead Pharmaceuticals received 524 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Entrada Therapeutics an outperform vote while only 65.45% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArrowhead PharmaceuticalsOutperform Votes53865.45% Underperform Votes28434.55% Entrada TherapeuticsOutperform Votes1477.78% Underperform Votes422.22% Which has better valuation & earnings, ARWR or TRDA? Entrada Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$240.74M10.06-$205.27M-$4.67-4.17Entrada Therapeutics$129.01M5.07-$6.68M$2.965.95 Is ARWR or TRDA more profitable? Entrada Therapeutics has a net margin of 43.63% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Entrada Therapeutics' return on equity of 35.16% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -152.95% -63.93% Entrada Therapeutics 43.63%35.16%20.41% Does the media favor ARWR or TRDA? In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Entrada Therapeutics. MarketBeat recorded 6 mentions for Arrowhead Pharmaceuticals and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.31 beat Arrowhead Pharmaceuticals' score of 1.06 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ARWR or TRDA? Arrowhead Pharmaceuticals has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. SummaryEntrada Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$654.72M$7.02B$5.32B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio5.9512.25127.5316.08Price / Sales5.07396.061,490.6892.20Price / CashN/A47.4339.5134.18Price / Book2.425.604.765.07Net Income-$6.68M$153.56M$118.77M$225.46M7 Day Performance3.59%-1.46%-0.38%0.06%1 Month Performance10.00%15.32%6.06%3.93%1 Year Performance13.55%43.07%38.14%32.50% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics2.4135 of 5 stars$17.60+2.7%$21.50+22.2%+13.5%$637.60M$129.01M5.95110Upcoming EarningsPositive NewsARWRArrowhead Pharmaceuticals4.2536 of 5 stars$20.38+1.4%$45.33+122.4%-24.4%$2.53B$19.65M-4.36400News CoverageIDYAIDEAYA Biosciences4.3456 of 5 stars$29.76+1.6%$55.45+86.3%-1.0%$2.51B$23.39M-13.5980Upcoming EarningsAnalyst ForecastAMPHAmphastar Pharmaceuticals4.6445 of 5 stars$50.58+0.6%$63.00+24.6%+11.6%$2.47B$712.89M16.161,761Upcoming EarningsAnalyst DowngradePositive NewsCGONCG Oncology3.0431 of 5 stars$36.83+1.2%$63.88+73.4%N/A$2.45B$650,000.000.0061Short Interest ↓ACADACADIA Pharmaceuticals4.6175 of 5 stars$14.50+1.1%$25.56+76.3%-35.4%$2.40B$890.53M80.56510Upcoming EarningsSRRKScholar Rock4.6384 of 5 stars$29.91+3.1%$33.29+11.3%+131.1%$2.39B$33.19M-13.47140Upcoming EarningsTWSTTwist Bioscience3.5724 of 5 stars$40.84+0.6%$51.22+25.4%+166.1%$2.39B$245.11M-10.69990LBPHLongboard Pharmaceuticals1.7935 of 5 stars$59.61+0.0%$59.56-0.1%+1,013.6%$2.32BN/A-27.7320Upcoming EarningsKROSKeros Therapeutics3.4249 of 5 stars$61.52+1.3%$89.11+44.8%+109.7%$2.31B$150,000.00-11.99100Upcoming EarningsShort Interest ↓Positive NewsSWTXSpringWorks Therapeutics1.223 of 5 stars$29.72+1.4%$68.50+130.5%+28.1%$2.21B$5.45M-6.71305 Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Amphastar Pharmaceuticals Alternatives CG Oncology Alternatives ACADIA Pharmaceuticals Alternatives Scholar Rock Alternatives Twist Bioscience Alternatives Longboard Pharmaceuticals Alternatives Keros Therapeutics Alternatives SpringWorks Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRDA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
